Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Gastrointestinal Therapeutics Market?

There has been robust growth in the size of the gastrointestinal therapeutics market in the last few years. The market is projected to swell from $39.99 billion in 2024 to $42.30 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this growth during the historical period include a spike in government spending on healthcare, improved rates of early diagnosis, enhanced gut health awareness programs, a surge in digestive disorders tied to lifestyle, and the rise of multidisciplinary treatment strategies.

Strong growth is anticipated in the gastrointestinal therapeutics market size over the coming years, with its value predicted to reach $52.41 billion in 2029, achieving a compound annual growth rate (CAGR) of 5.5%. The expansion during the forecast period can be ascribed to heightened demand for biologics and targeted therapies, a rising inclination towards personalised medicine, increased patient interest in combination therapies, a growing focus on therapeutics targeting the microbiome, and an increase in gastrointestinal complications associated with antibiotics. Major trends to watch during the forecast period include the integration of technology in endoscopic devices, the development of therapies based on the microbiome, the integration of digital health and remote monitoring, the utilization of multi-omics data in therapy development, and innovations in acid suppression therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

Which Industry Forces Are Driving The Gastrointestinal Therapeutics Market Forward?

The escalation in inflammatory bowel diseases is predicted to boost the expansion of the gastrointestinal therapeutics market in the future. Inflammatory bowel disease (IBD) is a long-lasting disease causing inflammation in the digestive tract, predominantly including Crohn’s disease and ulcerative colitis. The escalation in inflammatory bowel diseases can be attributed to genetic susceptibility leading to an irregular immune response to gut microbes. Gastrointestinal therapeutics facilitates the management and treatment of bowel diseases by focusing on the underlying inflammation, adjusting digestive functions and easing related symptoms to enhance patient outcomes. For example, in December 2023, the UK-based IBD Registry, a non-profit organization, registered over 5,300 individuals with inflammatory bowel diseases (IBD), indicating an increase of over 3,000 members from 2022. Consequently, the escalation in inflammatory bowel diseases is propelling the expansion of the gastrointestinal therapeutics market.

How Is The Gastrointestinal Therapeutics Market Organized By Different Segments?

The gastrointestinal therapeutics market covered in this report is segmented –

1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

What Current And Upcoming Trends Are Shaping The Gastrointestinal Therapeutics Market?

Focused on innovation, key players in the gastrointestinal therapeutics market are working towards improved patient adherence and overall efficiency of treatments by developing advanced therapies. This includes the use of sustained-release (SR) fixed-dose combination capsules. These oral medications slowly release a set of active ingredients over a period of time to establish consistent drug levels and help decrease the frequency of dosages. For example, Akums Drugs and Pharmaceuticals Limited, a pharmaceutical preparation manufacturing company based in India, unveiled their launch of rabeprazole + levosulpiride SR capsules for the treatment of gastrointestinal illnesses in June 2024. Rabeprazole, a proton pump inhibitor that minimizes stomach acid, is combined with levosulpiride, a prokinetic agent that boosts gut motility. The combination assists in alleviating symptoms including heartburn, acid reflux, bloating, and indigesticonsistently. It’s frequently recommended for managing diseases like gastroesophageal reflux, peptic ulcers, and other gastrointestinal (GI) conditions.

Who Are The Primary Market Leaders In The Gastrointestinal Therapeutics Market?

Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, Olympus Corporation, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

How Do Regional Dynamics Influence The Gastrointestinal Therapeutics Market Performance?

North America was the largest region in the gastrointestinal therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25768&type=smp

Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2025, By The Business Research Company

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastroesophageal Reflux Disease Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

Intestine Cancer Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model